Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth

• Main Authors: Luyuan Li, Xiaoyu Hu, Josiane E. Eid, Andrew E. Rosenberg, Breelyn A. Wilky, Yuguang Ban, Xiaodian Sun, Karina Galoian, Joanna DeSalvo, Jinbo Yue, Xi Steven Chen, Marzenna Blonska, Jonathan C. Trent
• Format: Article
• Language: English
• Published: MDPI AG 2020-01-01
• Series: Cancers
• Subjects: chondrosarcoma; idh mutation; integrin; 2-hydroxyglutarate; crispr/cas9
• Online Access: https://www.mdpi.com/2072-6694/12/1/141

Chondrosarcomas are a heterogeneous group of malignant bone tumors that produce hyaline cartilaginous matrix. Mutations in isocitrate dehydrogenase enzymes (IDH1/2) were recently described in several cancers, including conventional and dedifferentiated chondrosarcomas. These mutations lead to the inability of IDH to convert isocitrate into α-ketoglutarate (α-KG). Instead, α-KG is reduced into D-2-hydroxyglutarate (D-2HG), an oncometabolite. IDH mutations and D-2HG are thought to contribute to tumorigenesis due to the role of D-2HG as a competitive inhibitor of α-KG-dependent dioxygenases. However, the function of IDH mutations in chondrosarcomas has not been clearly defined. In this study, we knocked out mutant IDH1 (IDH1^mut) in two chondrosarcoma cell lines using the CRISPR/Cas9 system. We observed that D-2HG production, anchorage-independent growth, and cell migration were significantly suppressed in the IDH1^mut knockout cells. Loss of IDH1^mut also led to a marked attenuation of chondrosarcoma formation and D-2HG production in a xenograft model. In addition, RNA-Seq analysis of IDH1^mut knockout cells revealed downregulation of several integrin genes, including those of integrin alpha 5 (ITGA5) and integrin beta 5 (ITGB5). We further demonstrated that deregulation of integrin-mediated processes contributed to the tumorigenicity of IDH1-mutant chondrosarcoma cells. Our findings showed that IDH1^mut knockout abrogates chondrosarcoma genesis through modulation of integrins. This suggests that integrin molecules are appealing candidates for combinatorial regimens with IDH1^mut inhibitors for chondrosarcomas that harbor this mutation.